Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 139

1.

Diabetologie in der Hausarztpraxis: Mehr als nur Routine.

Parhofer KG.

MMW Fortschr Med. 2019 May;161(9):44. doi: 10.1007/s15006-019-0510-z. Review. German. No abstract available.

PMID:
31079372
2.

Current Role of Lipoprotein Apheresis.

Thompson G, Parhofer KG.

Curr Atheroscler Rep. 2019 May 1;21(7):26. doi: 10.1007/s11883-019-0787-5. Review.

3.

Apheresis for severe hypercholesterolaemia and elevated lipoprotein(a).

Waldmann E, Parhofer KG.

Pathology. 2019 Feb;51(2):227-232. doi: 10.1016/j.pathol.2018.10.016. Epub 2019 Jan 2. Review.

PMID:
30611543
4.

Feste Statindosis statt Zielwerte?

Baum E, Parhofer KG.

MMW Fortschr Med. 2018 Dec;160(21-22):28. doi: 10.1007/s15006-018-1216-3. German. No abstract available.

PMID:
30542879
5.

Lipoprotein (a) and Low-density lipoprotein apolipoprotein B metabolism following apheresis in patients with elevated lipoprotein(a) and coronary artery disease.

Ma L, Waldmann E, Ooi EMM, Chan DC, Barrett HPR, Watts GF, Parhofer KG.

Eur J Clin Invest. 2019 Feb;49(2):e13053. doi: 10.1111/eci.13053. Epub 2018 Dec 13.

PMID:
30447089
6.

[Lipidology - important changes of the last 10 years].

Parhofer KG.

MMW Fortschr Med. 2018 Nov;160(Suppl 3):42-44. doi: 10.1007/s15006-018-1120-x. Review. German. No abstract available.

PMID:
30421198
7.

CONTROVERSIAL ISSUES IN THE TREATMENT OF DYSLIPIDEMIAS IN PATIENTS WITH DIABETES MELLITUS.

Parhofer KG.

Rev Invest Clin. 2018;70(5):237-243. doi: 10.24875/RIC.18002574. Review.

8.

Lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients with familial hypercholesterolemia in Germany: The CaReHigh Registry.

Schmidt N, Dressel A, Grammer TB, Gouni-Berthold I, Julius U, Kassner U, Klose G, König C, Koenig W, Otte B, Parhofer KG, Reinhard W, Schatz U, Schunkert H, Steinhagen-Thiessen E, Vogt A, Laufs U, März W.

Atherosclerosis. 2018 Oct;277:314-322. doi: 10.1016/j.atherosclerosis.2018.08.050.

9.

Effects of a cluster-randomized school-based prevention program on physical activity and microvascular function (JuvenTUM 3).

Siegrist M, Hanssen H, Lammel C, Haller B, Koch AM, Stemp P, Dandl E, Liestak R, Parhofer KG, Vogeser M, Halle M.

Atherosclerosis. 2018 Nov;278:73-81. doi: 10.1016/j.atherosclerosis.2018.09.003. Epub 2018 Sep 8.

PMID:
30261471
10.

Corrigendum to: "Effect of mipomersen on LDL-cholesterol in patients with severe LDL-hypercholesterolaemia and atherosclerosis treated by lipoprotein apheresis (The MICA-Study)" [Atherosclerosis 259 (2017 Apr) 20-25].

Waldmann E, Vogt A, Crispin A, Altenhofer J, Riks I, Parhofer KG.

Atherosclerosis. 2018 Aug;275:461-462. doi: 10.1016/j.atherosclerosis.2018.05.020. Epub 2018 Jun 7. No abstract available.

PMID:
30153939
11.

Therapy and clinical trials.

Parhofer KG.

Curr Opin Lipidol. 2018 Aug;29(4):357-358. doi: 10.1097/MOL.0000000000000531. No abstract available.

PMID:
29994842
12.

Xanthoma Striatum Palmare.

Koehler VF, Parhofer KG.

N Engl J Med. 2018 May 10;378(19):e26. doi: 10.1056/NEJMicm1713658. No abstract available.

13.

Zuckerkranke beim Hausarzt in guten Händen.

Parhofer KG.

MMW Fortschr Med. 2018 Apr;160(7):40. doi: 10.1007/s15006-018-0431-2. Review. German. No abstract available.

PMID:
29663208
14.

Prevalence and sociodemographic determinants of adult obesity: a large representative household survey in a resource-constrained African setting with double burden of undernutrition and overnutrition.

Chigbu CO, Parhofer KG, Aniebue UU, Berger U.

J Epidemiol Community Health. 2018 Aug;72(8):702-707. doi: 10.1136/jech-2018-210573. Epub 2018 Mar 29.

PMID:
29599385
15.

A Walnut-Enriched Diet Affects Gut Microbiome in Healthy Caucasian Subjects: A Randomized, Controlled Trial.

Bamberger C, Rossmeier A, Lechner K, Wu L, Waldmann E, Fischer S, Stark RG, Altenhofer J, Henze K, Parhofer KG.

Nutrients. 2018 Feb 22;10(2). pii: E244. doi: 10.3390/nu10020244.

16.

Atherosklerose-Patienten in der Hausarztpraxis: Wen wie behandeln?

Parhofer KG.

MMW Fortschr Med. 2018 Jan;160(1):38-39. doi: 10.1007/s15006-018-0089-9. Review. German. No abstract available.

PMID:
29335945
17.

[PCSK9 inhibitors: For which patients? For which indication? What to consider?]

Busygina K, Parhofer KG.

MMW Fortschr Med. 2018 Jan;160(1):43-46. doi: 10.1007/s15006-018-0091-2. Review. German. No abstract available.

PMID:
29335943
18.

Predictors of Quality of Life and Other Patient-Reported Outcomes in the PANORAMA Multinational Study of People With Type 2 Diabetes.

Bradley C, Eschwège E, de Pablos-Velasco P, Parhofer KG, Simon D, Vandenberghe H, Gönder-Frederick L.

Diabetes Care. 2018 Feb;41(2):267-276. doi: 10.2337/dc16-2655. Epub 2017 Nov 28.

PMID:
29183910
19.

A Walnut-Enriched Diet Reduces Lipids in Healthy Caucasian Subjects, Independent of Recommended Macronutrient Replacement and Time Point of Consumption: a Prospective, Randomized, Controlled Trial.

Bamberger C, Rossmeier A, Lechner K, Wu L, Waldmann E, Stark RG, Altenhofer J, Henze K, Parhofer KG.

Nutrients. 2017 Oct 6;9(10). pii: E1097. doi: 10.3390/nu9101097.

20.

New approaches to address dyslipidemia.

Parhofer KG.

Curr Opin Lipidol. 2017 Dec;28(6):452-457. doi: 10.1097/MOL.0000000000000456. Review.

PMID:
28902717

Supplemental Content

Loading ...
Support Center